ISDS Case Map
intellectual property
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
The industry is working to get US senators on record in support of including the protections it lost in NAFTA 2.0 in future trade agreements with other countries.
India's decision to pull out of RCEP means its policy on access to inexpensive drugs will not be under pressure.
Proper mandatory licenses will be exempt from claims for expropriation under the China BIT model.
Many requirements of the original USMCA have already been met by recent changes in Canadian IP legislation, but more amendments will be required to implement the USMCA.
The hard part of the trade dispute will cover long-standing issues relating to intellectual property violations and forced technology transfer by China, as well as subsidization of Chinese industries.
Canada’s intellectual protection rights system was also slammed for being too clement.
India is making efforts to speed up free trade negotiations with the EFTA countries comprising Switzerland, Norway, Iceland and Leichtenstein in parallel with its discussions with the European Union on a similar pact.
